Webster Bank’s Madrigal Pharmaceuticals MDGL Stock Holding History

Webster Bank’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-6	Closed	-$3.14K	–	729
2026 Q1	$3.14K	Hold	6	–	–	﹤0.01%	615
2025 Q4	$3.49K	Hold	6	–	–	﹤0.01%	594
2025 Q3	$2.75K	Hold	6	–	–	﹤0.01%	600
2025 Q2	$1.82K	Buy	+6	New	+$1.79K	﹤0.01%	618

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Webster Bank's MDGL Position: Q2 2026 in Review

Webster Bank sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2026, closing a stake of 6 shares — an estimated $3.14K sold.

Webster Bank first reported a position in MDGL in Q2 2025 and held it in 4 quarters. The position peaked at $3.49K in Q4 2025. 413 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

Webster Bank reported no remaining Madrigal Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Webster Bank sold 6 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $3.14K.
Webster Bank first reported a position in Madrigal Pharmaceuticals in Q2 2025 and held it in 4 quarters.
Webster Bank's Madrigal Pharmaceuticals position peaked at $3.49K in Q4 2025.
413 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Webster Bank's 13F filing for Q2 2026, filed 20 Jul 2026.